Advertisement

DARU Journal of Pharmaceutical Sciences

, Volume 27, Issue 2, pp 721–733 | Cite as

Ellagic acid reduces methotrexate-induced apoptosis and mitochondrial dysfunction via up-regulating Nrf2 expression and inhibiting the IĸBα/NFĸB in rats

  • Reihaneh Ebrahimi
  • Mohammad Reza Sepand
  • Seyed Afshin Seyednejad
  • Ameneh Omidi
  • Mostafa Akbariani
  • Maryam Gholami
  • Omid SabzevariEmail author
Research article
  • 56 Downloads

Abstract

Background

The clinical application of methotrexate (MTX), an efficacious cytotoxic drug, is restricted due to its associated liver toxicity. Ellagic acid (EA), a natural polyphenol, possesses hepatoprotective, antioxidant and anti-inflammatory properties.

Objectives

The present study seeks to address the hepatoprotective effects of Ellagic acid (EA) against MTX-mediated oxidative stress (OS) and widen our current knowledge of the underlying molecular mechanisms of MTX toxicity.

Methods

Wistar rats were orally given EA (5 mg/kg and 10 mg/kg) for 10 successive days and at the end of the third day they were administered a single dose of MTX (20 mg/kg i.p).

Results

After performing biochemical analysis, liver enzymes and malondialdehyde were significantly higher in the MTX group, indicating hepatic oxidative damage. MTX-induced OS was further confirmed with observation of events such as reactive oxygen species (ROS) overproduction, mitochondrial outer membrane potential decrease, mitochondrial swelling, cytochrome c release and caspase-3/9 increase, resulting in apoptosis. Furthermore, overexpression of pro-inflammatory factors such as nuclear factor kappa B (NF-ĸB) and interleukin 6 (IL-6) indicated the MTX-induced inflammation in MTX-treated group. Interestingly, EA was able to significantly prevent OS, mitochondrial dysfunction, apoptosis and inflammation induced by MTX. Also, EA-treated rats demonstrated significant upregulation of both nuclear factor erythroid 2-related factor 2 (Nrf2) and hemoxygenase-1 (HO-1), which were considerably downregulated in MTX-treated rats.

Conclusions

EA protects rats against MTX-induced apoptosis and mitochondrial dysfunction via up-Regulating Nrf2 and HO-1 expression and inhibiting the NF-κB signaling pathway. Therefore, EA may protect patients against MTX-induced hepatotoxicity and encourage its clinical application.

Graphical abstract

Beneficial effect of Ellagic acid (EA) on Methotrexate (MTX)-induced liver injury: molecular mechanism.

Keywords

Ellagic acid Mitochondrial dysfunction Oxidative stress Inflammation Apoptosis 

Notes

Acknowledgements

This work was supported by Vice Chancellor for Research, Tehran University of Medical Sciences, Tehran, Iran under Grant (96-03-169-36364).

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this article.

References

  1. 1.
    Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–82.  https://doi.org/10.1016/S0140-6736(08)61000-4.CrossRefPubMedGoogle Scholar
  2. 2.
    Gangjee A, Kurup S, Namjoshi O. Dihydrofolate reductase as a target for chemotherapy in parasites. Curr Pharm Des. 2007;13(6):609–39.CrossRefGoogle Scholar
  3. 3.
    Neradil J, Pavlasova G, Veselska R. New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. Klin Onkol. 2012;25(Suppl 2):2S87–92.PubMedGoogle Scholar
  4. 4.
    Sramek M, Neradil J, Veselska R. Much more than you expected: the non-DHFR-mediated effects of methotrexate. Biochim Biophys Acta Gen Subj. 2017;1861(3):499–503.  https://doi.org/10.1016/j.bbagen.2016.12.014.CrossRefPubMedGoogle Scholar
  5. 5.
    Cetiner M, Sener G, Sehirli AO, Eksioglu-Demiralp E, Ercan F, Sirvanci S, et al. Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death. Toxicol Appl Pharmacol. 2005;209(1):39–50.  https://doi.org/10.1016/j.taap.2005.03.009.CrossRefPubMedGoogle Scholar
  6. 6.
    Elango T, Dayalan H, Gnanaraj P, Malligarjunan H, Subramanian S. Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin Exp Med. 2014;14(4):431–7.  https://doi.org/10.1007/s10238-013-0252-7.CrossRefPubMedGoogle Scholar
  7. 7.
    Paul M, Hemshekhar M, Thushara RM, Sundaram MS, NaveenKumar SK, Naveen S, et al. Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N-Acetylcysteine and N-Acetylcysteine amide. PLoS One. 2015;10(6):e0127558.  https://doi.org/10.1371/journal.pone.0127558.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Al Maruf A, O'Brien PJ, Naserzadeh P, Fathian R, Salimi A, Pourahmad J. Methotrexate induced mitochondrial injury and cytochrome c release in rat liver hepatocytes. Drug Chem Toxicol. 2018;41(1):51–61.  https://doi.org/10.1080/01480545.2017.1289221.CrossRefPubMedGoogle Scholar
  9. 9.
    Mahmoud AM, Hussein OE, Hozayen WG, Abd El-Twab SM. Methotrexate hepatotoxicity is associated with oxidative stress, and down-regulation of PPARgamma and Nrf2: protective effect of 18beta-Glycyrrhetinic acid. Chem Biol Interact. 2017;270:59–72.  https://doi.org/10.1016/j.cbi.2017.04.009.CrossRefPubMedGoogle Scholar
  10. 10.
    Usta C, Ozdemir S, Schiariti M, Puddu PE. The pharmacological use of ellagic acid-rich pomegranate fruit. Int J Food Sci Nutr. 2013;64(7):907–13.  https://doi.org/10.3109/09637486.2013.798268.CrossRefPubMedGoogle Scholar
  11. 11.
    Oveissi V, Ram M, Bahramsoltani R, Ebrahimi F, Rahimi R, Naseri R, et al. Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective. Daru. 2019;27:389–406.  https://doi.org/10.1007/s40199-019-00255-6.CrossRefPubMedGoogle Scholar
  12. 12.
    Bahramsoltani R, Ebrahimi F, Farzaei MH, Baratpourmoghaddam A, Ahmadi P, Rostamiasrabadi P, et al. Dietary polyphenols for atherosclerosis: a comprehensive review and future perspectives. Crit Rev Food Sci Nutr. 2019;59(1):114–32.  https://doi.org/10.1080/10408398.2017.1360244.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen P, Chen F, Zhou B. Antioxidative, anti-inflammatory and anti-apoptotic effects of ellagic acid in liver and brain of rats treated by D-galactose. Sci Rep. 2018;8(1):1465.  https://doi.org/10.1038/s41598-018-19732-0.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hseu YC, Chou CW, Senthil Kumar KJ, Fu KT, Wang HM, Hsu LS, et al. Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes. Food Chem Toxicol. 2012;50(5):1245–55.  https://doi.org/10.1016/j.fct.2012.02.020.CrossRefPubMedGoogle Scholar
  15. 15.
    Mukherjee S, Ghosh S, Choudhury S, Adhikary A, Manna K, Dey S, et al. Pomegranate reverses methotrexate-induced oxidative stress and apoptosis in hepatocytes by modulating Nrf2-NF-kappaB pathways. J Nutr Biochem. 2013;24(12):2040–50.  https://doi.org/10.1016/j.jnutbio.2013.07.005.CrossRefPubMedGoogle Scholar
  16. 16.
    Razavi-Azarkhiavi K, Ali-Omrani M, Solgi R, Bagheri P, Haji-Noormohammadi M, Amani N, et al. Silymarin alleviates bleomycin-induced pulmonary toxicity and lipid peroxidation in mice. Pharm Biol. 2014;52(10):1267–71.  https://doi.org/10.3109/13880209.2014.889176.CrossRefPubMedGoogle Scholar
  17. 17.
    Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27(3):502–22.CrossRefGoogle Scholar
  18. 18.
    Bodaghi-Namileh V, Sepand MR, Omidi A, Aghsami M, Seyednejad SA, Kasirzadeh S, et al. Acetyl-l-carnitine attenuates arsenic-induced liver injury by abrogation of mitochondrial dysfunction, inflammation, and apoptosis in rats. Environ Toxicol Pharmacol. 2018;58:11–20.  https://doi.org/10.1016/j.etap.2017.12.005.CrossRefPubMedGoogle Scholar
  19. 19.
    Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76–85.CrossRefGoogle Scholar
  20. 20.
    Sepand MR, Ghahremani MH, Razavi-Azarkhiavi K, Aghsami M, Rajabi J, Keshavarz-Bahaghighat H, et al. Ellagic acid confers protection against gentamicin-induced oxidative damage, mitochondrial dysfunction and apoptosis-related nephrotoxicity. J Pharm Pharmacol. 2016;68(9):1222–32.  https://doi.org/10.1111/jphp.12589.CrossRefPubMedGoogle Scholar
  21. 21.
    Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31(1):241–6.  https://doi.org/10.1002/hep.510310136.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474–85.  https://doi.org/10.1056/NEJMra021844.CrossRefPubMedGoogle Scholar
  23. 23.
    Cetinkaya A, Bulbuloglu E, Kurutas EB, Kantarceken B. N-acetylcysteine ameliorates methotrexate-induced oxidative liver damage in rats. Med Sci Monit. 2006;12(8):BR274–8.PubMedGoogle Scholar
  24. 24.
    Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, Cass B, et al. Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis. 2005;26(4):821–6.  https://doi.org/10.1093/carcin/bgi024.CrossRefPubMedGoogle Scholar
  25. 25.
    Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 2004;39(4):336–9.  https://doi.org/10.1093/alcalc/agh074.CrossRefPubMedGoogle Scholar
  26. 26.
    Safaei F, Mehrzadi S, Khadem Haghighian H, Hosseinzadeh A, Nesari A, Dolatshahi M, et al. Protective effects of gallic acid against methotrexate-induced toxicity in rats. Acta Chir Belg. 2018;118(3):152–60.  https://doi.org/10.1080/00015458.2017.1394672.CrossRefPubMedGoogle Scholar
  27. 27.
    Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan SC. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam Clin Pharmacol. 2009;23(6):735–45.  https://doi.org/10.1111/j.1472-8206.2009.00722.x.CrossRefPubMedGoogle Scholar
  28. 28.
    Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52.  https://doi.org/10.1164/rccm.200510-1666ST.CrossRefPubMedGoogle Scholar
  29. 29.
    Aghsami M, Sharifzadeh M, Sepand MR, Yazdankhah M, Seyednejad SA, Pourahmad J. A cAMP analog attenuates beta-amyloid (1-42)-induced mitochondrial dysfunction and spatial learning and memory deficits. Brain Res Bull. 2018;140:34–42.  https://doi.org/10.1016/j.brainresbull.2018.03.016.CrossRefPubMedGoogle Scholar
  30. 30.
    Jahovic N, Cevik H, Sehirli AO, Yegen BC, Sener G. Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res. 2003;34(4):282–7.CrossRefGoogle Scholar
  31. 31.
    Kopff M, Zakrzewska I, Czernicki J, Klem J, Strzelczyk M, Chmielewski H. Red blood cell superoxide dismutase and catalase activities in patients suffering from multiple sclerosis treated with adrenocorticotropic hormone. Pol J Pharmacol. 1996;48(4):441–5.CrossRefGoogle Scholar
  32. 32.
    Rios JL, Giner RM, Marin M, Recio MC. A pharmacological update of Ellagic acid. Planta Med. 2018;84(15):1068–93.  https://doi.org/10.1055/a-0633-9492.CrossRefPubMedGoogle Scholar
  33. 33.
    Haghi-Aminjan H, Asghari MH, Goharbari MH, Abdollahi M. A systematic review on potential mechanisms of minocycline in kidney diseases. Pharmacol Rep. 2017;69(4):602–9.  https://doi.org/10.1016/j.pharep.2017.02.001.CrossRefPubMedGoogle Scholar
  34. 34.
    Keshavarz-Bahaghighat H, Sepand MR, Ghahremani MH, Aghsami M, Sanadgol N, Omidi A, et al. Acetyl-L-Carnitine attenuates arsenic-induced oxidative stress and hippocampal mitochondrial dysfunction. Biol Trace Elem Res. 2018;184(2):422–35.  https://doi.org/10.1007/s12011-017-1210-0.CrossRefPubMedGoogle Scholar
  35. 35.
    Haghi-Aminjan H, Asghari MH, Farhood B, Rahimifard M, Hashemi Goradel N, Abdollahi M. The role of melatonin on chemotherapy-induced reproductive toxicity. J Pharm Pharmacol. 2018;70(3):291–306.  https://doi.org/10.1111/jphp.12855.CrossRefPubMedGoogle Scholar
  36. 36.
    El-Sheikh AA, Morsy MA, Hamouda AH. Protective mechanisms of Thymoquinone on methotrexate-induced intestinal toxicity in rats. Pharmacogn Mag. 2016;12(Suppl 1):S76–81.  https://doi.org/10.4103/0973-1296.176106.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Copple IM, Goldring CE, Kitteringham NR, Park BK. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology. 2008;246(1):24–33.  https://doi.org/10.1016/j.tox.2007.10.029.CrossRefPubMedGoogle Scholar
  38. 38.
    Kovac S, Angelova PR, Holmstrom KM, Zhang Y, Dinkova-Kostova AT, Abramov AY. Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim Biophys Acta. 2015;1850(4):794–801.  https://doi.org/10.1016/j.bbagen.2014.11.021.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Aleksunes LM, Manautou JE. Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol. 2007;35(4):459–73.  https://doi.org/10.1080/01926230701311344.CrossRefPubMedGoogle Scholar
  40. 40.
    Abdo S, Zhang SL, Chan JS. Reactive oxygen species and nuclear factor Erythroid 2-related factor 2 activation in diabetic nephropathy: a hidden target. J Diabetes Metab. 2015;6(6).  https://doi.org/10.4172/2155-6156.1000547.
  41. 41.
    Ding Y, Zhang B, Zhou K, Chen M, Wang M, Jia Y, et al. Dietary ellagic acid improves oxidant-induced endothelial dysfunction and atherosclerosis: role of Nrf2 activation. Int J Cardiol. 2014;175(3):508–14.  https://doi.org/10.1016/j.ijcard.2014.06.045.CrossRefPubMedGoogle Scholar
  42. 42.
    Sheibani M, Faghir-Ghanesefat H, Dehpour S, Keshavarz-Bahaghighat H, Sepand MR, Ghahremani MH, et al. Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model. Inflammopharmacology. 2019;27:1071–80.  https://doi.org/10.1007/s10787-019-00586-5.CrossRefPubMedGoogle Scholar
  43. 43.
    Soares MP, Seldon MP, Gregoire IP, Vassilevskaia T, Berberat PO, Yu J, et al. Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol. 2004;172(6):3553–63.  https://doi.org/10.4049/jimmunol.172.6.3553.CrossRefPubMedGoogle Scholar
  44. 44.
    Ahad A, Ganai AA, Mujeeb M, Siddiqui WA. Ellagic acid, an NF-kappaB inhibitor, ameliorates renal function in experimental diabetic nephropathy. Chem Biol Interact. 2014;219:64–75.  https://doi.org/10.1016/j.cbi.2014.05.011.CrossRefPubMedGoogle Scholar
  45. 45.
    Jun CD, Kim Y, Choi EY, Kim M, Park B, Youn B, et al. Gliotoxin reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice: evidence of the connection between heme oxygenase-1 and the nuclear factor-kappaB pathway in vitro and in vivo. Inflamm Bowel Dis. 2006;12(7):619–29.  https://doi.org/10.1097/01.ibd.0000225340.99108.8a.CrossRefPubMedGoogle Scholar
  46. 46.
    Yeh PY, Li CY, Hsieh CW, Yang YC, Yang PM, Wung BS. CO-releasing molecules and increased heme oxygenase-1 induce protein S-glutathionylation to modulate NF-kappaB activity in endothelial cells. Free Radic Biol Med. 2014;70:1–13.  https://doi.org/10.1016/j.freeradbiomed.2014.01.042.CrossRefPubMedGoogle Scholar
  47. 47.
    Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci U S A. 1994;91(13):5987–91.  https://doi.org/10.1073/pnas.91.13.5987.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Andreadi CK, Howells LM, Atherfold PA, Manson MM. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol. 2006;69(3):1033–40.  https://doi.org/10.1124/mol.105.018374.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Toxicology and Poisoning Research Centre, Department of Toxicology and Pharmacology, International Campus, Faculty of PharmacyTehran University of Medical SciencesTehranIran
  2. 2.Department of Anatomical Sciences, Faculty of Medical SciencesTarbiat Modares UniversityTehranIran

Personalised recommendations